<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2019.81002</article-id><article-id pub-id-type="publisher-id">PI-28245</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20190100000_58573429.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  德拉沙星：一种新型氟喹诺酮类广谱抗菌药
  Delafloxacin: A Novel Fluoroquinolones Broad-Spectrum Antibacterial
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>忠秋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>冰弥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>宇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>辽宁大学药学院，辽宁 沈阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>27</day><month>12</month><year>2018</year></pub-date><volume>08</volume><issue>01</issue><fpage>9</fpage><lpage>15</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   德拉沙星是一种新型的氟喹诺酮类广谱抗菌药，具有阴离子特性，在酸性条件下具有较好的抗菌活性。通过抑制细菌DNA的复制过程，从而达到杀菌的作用。对革兰氏阳性菌，革兰氏阴性菌和厌氧菌都具有较好的抗菌活性。2017年6月获得美国FDA批准用于治疗急性细菌性皮肤和皮肤结构感染。有口服片剂和注射用粉针两种剂型，推荐剂量为静脉注射300 mg或口服450 mg。具有较好的安全性和耐受性，没有明显的心脏QT间期延长和光毒性。本文对德拉沙星的基本性质，抗菌活性，作用机制，药动学，药效学，安全性和耐受性等方面进行介绍。 Delafloxacin is a novel fluoroquinolones antibacterial with anionic properties and good antibacterial activity under acidic conditions. By inhibiting the activity of topoisomerase IV and DNA helicases, the replication of bacterial DNA was blocked and sterilization is achieved. It has a wide range of antibacterial activities for gram-positive bacteria, Gramnegative and anaerobic bacteria. In June 2017, it was approved by the US FDA for the treatment of acute bacterial skin and skin structural infections. There are two dosage forms of oral tablet and injection powder. The recommended dose is intravenous injection of 300 mg or oral 450 mg. It has good safety and tolerability, no heart QT prolongation and phototoxicity. The basic properties, antibacterial activity, mechanism of action, pharmacokinetics, pharmacodynamics, safety and tolerance of delafloxacin were reviewed in this paper. 
  
 
</p></abstract><kwd-group><kwd>德拉沙星，氟喹诺酮，抗菌药，作用机制, Delafloxacin</kwd><kwd> Fluoroquinolones</kwd><kwd> Antibacterial Drugs</kwd><kwd> Mechanism of Action</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>德拉沙星：一种新型氟喹诺酮类广谱抗菌药<sup> </sup></title><p>郭忠秋，刘冰弥，刘宇<sup>*</sup></p><p>辽宁大学药学院，辽宁 沈阳</p><p><img src="//html.hanspub.org/file/2-1710168x1_hanspub.png" /></p><p>收稿日期：2018年12月10日；录用日期：2018年12月20日；发布日期：2018年12月27日</p><disp-formula id="hanspub.28245-formula52"><graphic xlink:href="//html.hanspub.org/file/2-1710168x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>德拉沙星是一种新型的氟喹诺酮类广谱抗菌药，具有阴离子特性，在酸性条件下具有较好的抗菌活性。通过抑制细菌DNA的复制过程，从而达到杀菌的作用。对革兰氏阳性菌，革兰氏阴性菌和厌氧菌都具有较好的抗菌活性。2017年6月获得美国FDA批准用于治疗急性细菌性皮肤和皮肤结构感染。有口服片剂和注射用粉针两种剂型，推荐剂量为静脉注射300 mg或口服450 mg。具有较好的安全性和耐受性，没有明显的心脏QT间期延长和光毒性。本文对德拉沙星的基本性质，抗菌活性，作用机制，药动学，药效学，安全性和耐受性等方面进行介绍。</p><p>关键词 :德拉沙星，氟喹诺酮，抗菌药，作用机制</p><disp-formula id="hanspub.28245-formula53"><graphic xlink:href="//html.hanspub.org/file/2-1710168x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1710168x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1710168x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>抗菌药物对于对抗致病菌感染，降低疾病发生率，增强体质具有十分重要的作用。但是，随着抗菌药的广泛使用，抗菌药物的滥用情况也越来越严重，致病菌的耐药性逐渐增加，导致抗菌药的抗菌效力不断下降 [<xref ref-type="bibr" rid="hanspub.28245-ref1">1</xref>]。由耐药性病原体引起的感染病越来越具有挑战性，革兰氏阴性和革兰氏阳性病原体的耐药性不断增加，导致高的发病率和死亡率，这些现象在医学界引起了广泛关注 [<xref ref-type="bibr" rid="hanspub.28245-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.28245-ref3">3</xref>]。在细菌耐药性增加的时代，急性细菌性皮肤和皮肤结构感染(acute bacterial skin and skin structure infections, ABSSSI)作为临床常见的疾病之一，其发病率和住院率逐年上升，并伴有严重的并发症，是一个具有挑战性的医学难题 [<xref ref-type="bibr" rid="hanspub.28245-ref4">4</xref>]。耐甲氧西林金黄色葡萄球菌(methicillin-resistant staphylococcus aureus, MRSA)是ABSSSI最常见的致病病原体，MRSA对酸性环境的耐受性较好，能在脓肿等偏酸性的组织中存活，而一般抗菌药物对该组织的抗菌活性都会减弱 [<xref ref-type="bibr" rid="hanspub.28245-ref5">5</xref>]。因此，为了减缓传统抗菌药物的耐药性，仍然需要不断研发具有较高抗菌活性的新型抗菌药，用来治疗包含MRSA在内的多重耐药细菌感染。</p><p>喹诺酮类药物是在1962年通过萘啶酸的批准而引入临床实践的 [<xref ref-type="bibr" rid="hanspub.28245-ref6">6</xref>]。通过对喹诺酮类化合物进行结构修饰，以调节它们的药物活性，药代动力学特性和安全性，现已成功用于治疗各种由革兰氏阳性和革兰氏阴性细菌引起的腹腔内，皮肤和皮肤结构，尿道和呼吸道感染 [<xref ref-type="bibr" rid="hanspub.28245-ref7">7</xref>]。德拉沙星是一种新型的氟喹诺酮类药物，能对抗革兰氏阳性和革兰氏阴性病原体，德拉沙星在抗革兰氏阳性菌上具有比其他喹诺酮类药物更有效的活性 [<xref ref-type="bibr" rid="hanspub.28245-ref8">8</xref>]。德拉沙星具有独特的作用机制，是临床使用的唯一一类直接靶向DNA复制中的两种必需酶的抗生素 [<xref ref-type="bibr" rid="hanspub.28245-ref9">9</xref>]。德拉沙星通过抑制细菌拓扑异构酶IV和DNA螺旋酶的活性，阻碍细菌DNA复制、转录等过程，最终导致细菌死亡 [<xref ref-type="bibr" rid="hanspub.28245-ref10">10</xref>]。与其他氟喹诺酮类药物相比，德拉沙星具有阴离子特性，能够增强它在酸性环境中的抗菌活性，使其在酸性环境下积累量是其他药物的10倍，这种特殊的性质使其能够更加有效地杀灭酸性环境下的MRSA [<xref ref-type="bibr" rid="hanspub.28245-ref11">11</xref>]。德拉沙星的药效通过两个III期临床试验进行了验证，其单药疗效不比万古霉素和氨曲南联合用药的效果差，安全性和耐受性良好，无心脏QT间期延长和光毒性，也没有显示对肝功能、肾功能和葡萄糖利用的不良影响 [<xref ref-type="bibr" rid="hanspub.28245-ref12">12</xref>]。</p></sec><sec id="s4"><title>2. 德拉沙星简介</title><p>德拉沙星是由日本Wakunaga制药公司与美国Melinta公司共同研制开发的新型氟喹诺酮类广谱抗菌药，对大多数病原菌引起的ABSSSIs以及呼吸道感染具有良好的抗菌活性 [<xref ref-type="bibr" rid="hanspub.28245-ref13">13</xref>]。2017年6月19日美国FDA首次批准其上市，临床上用于治疗ABSSSI [<xref ref-type="bibr" rid="hanspub.28245-ref14">14</xref>]。以德拉沙星葡甲胺盐的形式存在，有注射用粉针和口服片剂两种剂型，推荐使用剂量为静脉注射300 mg或口服450 mg [<xref ref-type="bibr" rid="hanspub.28245-ref15">15</xref>]。德拉沙星的商品名是baxdela，通用名是delafloxacin，化学名称为1-(6-氨基-3,5-二氟-2-吡啶基)-8-氯-6-氟-1,4-二氢-7-(3-羟基-1-氮杂环丁基)-4-氧代-3-喹啉羧酸，化学式为C<sub>18</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>，相对分子量为440.76 [<xref ref-type="bibr" rid="hanspub.28245-ref16">16</xref>]。结构式如图1所示。</p><p>图1. 德拉沙星的结构式</p><p>德拉沙星的化学结构与其他大多数氟喹诺酮类药物不同，主要体现在以下3点 [<xref ref-type="bibr" rid="hanspub.28245-ref17">17</xref>] ：1) 它在C-7位缺乏强碱性基团，使其呈弱酸性，可以增强在弱酸性环境中的抗菌活性；2) C-8位的氯(与C-6位的氟一致)会对芳环产生强烈的吸电子效应，有助于提高分子的稳定性；3) 在N-1位上存在一个芳香杂环取代，与其他氟喹诺酮类相比，可以形成更大的分子表面。通过对氟喹诺酮类化合物的构效关系进行研究发现，C-3位羧基和C-4位的羰基是保持抗菌活性必需的基团，C-6位的氟和C-8位的氯有助于增强其抗菌活性 [<xref ref-type="bibr" rid="hanspub.28245-ref18">18</xref>]。</p></sec><sec id="s5"><title>3. 抗菌活性</title><p>德拉沙星作为弱酸性分子，在微酸性pH下，多数形式以中性状态存在，容易透过生物膜进入细菌。中性pH下主要以阴离子形式存在，从而在细菌内蓄积 [<xref ref-type="bibr" rid="hanspub.28245-ref19">19</xref>]。这种特殊的性质可以解释为什么在酸性pH下，德拉沙星会在细菌中积累更多。在体内局部感染部位一般为酸性环境，基于这些特点，可以在吞噬溶酶体，炎症细胞和感染组织等低pH环境下增强德拉沙星的抗菌活性 [<xref ref-type="bibr" rid="hanspub.28245-ref20">20</xref>]。德拉沙星是一种双靶向的氟喹诺酮类化合物，可以与DNA和拓扑异构酶IV或DNA促旋酶形成三元复合物，从而抑制细菌DNA形成超螺旋，破坏DNA的复制过程，从而达到杀菌的作用 [<xref ref-type="bibr" rid="hanspub.28245-ref21">21</xref>]。德拉沙星在体外对革兰氏阳性菌和革兰氏阴性菌的杀菌活性呈浓度依赖性，对MRSA的抗菌活性比其他氟喹诺酮类药物更强。德拉沙星对MRSA敏感株110 (左氧氟沙星敏感株)、124株(三重突变株)和165株(四重突变株)的最小杀菌浓度(minimum bactericidal concentration, MBC)分别为0.008 μg/mL，0.5 μg/mL和8 μg/mL，而左氧氟沙星的MBC分别为0.5 μg/mL，8 μg/mL和大于32 μg/mL。大部分浓度的德拉沙星和左氧氟沙星对MRSA株110的杀菌活性均在6小时观察到，德拉沙星在16倍最小抑菌浓度(minimal inhibitory concentration, MIC)时对MRSA菌株124的杀灭速度比相同浓度的左氧氟沙星更快，在16倍和32倍MIC时对MRSA株165的杀菌活性在24小时观察到 [<xref ref-type="bibr" rid="hanspub.28245-ref22">22</xref>]。</p></sec><sec id="s6"><title>4. 药动学</title><p>通过三项I期临床试验对德拉沙星的药代动力学特征进行了研究。首先是一项双盲，随机，单次递增剂量研究，向52名健康志愿者静脉注射剂量分别为300 mg、450 mg、600 mg、750 mg、900 mg和1200 mg的德拉沙星。药代动力学分析显示，在所研究的剂量范围内(300 mg至1200 mg)，德拉沙星的最大血药浓度(C<sub>max</sub>)随给药剂量成比例增加，而药时曲线下面积(AUC)的增加超过给药剂量的比例。在所有测试的剂量中达到最大血药浓度的时间(T<sub>max</sub>)为1.0小时。全身清除率(CL)和分布容积(Vd)分别在7.59 L/h至12.53 L/h之间和30.2 L至38.50 L之间。肾清除率约占全身清除率的32.1%到39.7%，并且有随着德拉沙星剂量的增加而降低的趋势 [<xref ref-type="bibr" rid="hanspub.28245-ref23">23</xref>]。在第二项研究中，向健康志愿者每日两次静脉给药德拉沙星300 mg，共14天，评估多次给药后药物累积的程度。比较第1天和第14天的药物暴露时，未观察到明显的德拉沙星蓄积，累积率为1.09 [<xref ref-type="bibr" rid="hanspub.28245-ref23">23</xref>]。第三项研究是在56名健康志愿者中进行的一个2期2序列交叉研究，以评估单次给药剂量为口服450 mg和静脉注射300 mg之间的生物等效性。结果显示平均绝对生物利用度为58.8%，口服450 mg与静脉给药300 mg等效 [<xref ref-type="bibr" rid="hanspub.28245-ref23">23</xref>]。</p><p>在开放标签的I期临床试验中研究了德拉沙星的排泄率和途径，在健康男性志愿者中静脉注射300 mg用<sup>14</sup>C标记的德拉沙星后，观察德拉沙星的排泄情况。研究结果表明，德拉沙星的氧化代谢很低，主要经肾脏排泄。尿排泄量约占放射性总量的65.7% &#177; 4.97%，144小时粪便排泄量占放射性量的28.5% &#177; 4.92%。德拉沙星占回收剂量的69.7% (41.2%尿液和28.5%粪便)，而葡萄糖醛酸(德拉沙星主要循环代谢物，排泄在尿液中)占回收剂量的20.4%。总的来说，大约66%的剂量在尿液中被回收，主要是没有发生改变的德拉沙星，大约29%是由于胆汁排泄或肠道消除而在粪便中回收。德拉沙星主要与白蛋白结合，通过平衡透析确定了德拉沙星人血浆蛋白结合的含量约为84% [<xref ref-type="bibr" rid="hanspub.28245-ref24">24</xref>]。</p><p>一项双盲，使用安慰剂作为对照的I期临床试验研究了年龄和性别对德拉沙星药代动力学性质的影响。结果显示，女性和男性的药代动力学参数具有可比性，而老年人的C<sub>max</sub>和AUC<sub>0-∞</sub>显著高于年轻人，这可能是由于老年人的肌酐清除率较低的原因(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.28245-ref25">25</xref>]。肾损伤似乎显著影响了德拉沙星的清除率，与肾功能正常的患者相比，严重肾脏疾病患者的药物CL约减半 [<xref ref-type="bibr" rid="hanspub.28245-ref26">26</xref>]。在存在严重肾损伤(肌酐清除率 &lt; 30 mL/min)的情况下，建议在静脉给药途径中将给药剂量减至200 mg。在I期开放标签单次300 mg静脉剂量研究中，根据Child-Pugh分级系统将18名肝损伤患者均匀分成3组(A组：轻度；B组：中等；C组：严重)并且与18名健康对照者1:1匹配。肝损伤患者的平均德拉沙星AUC<sub>0-∞</sub>，C<sub>max</sub>，暴露和清除率与健康受试者无显著差异 [<xref ref-type="bibr" rid="hanspub.28245-ref27">27</xref>]。基于这些数据，不需要对肝损伤患者进行德拉沙星的剂量调整。</p></sec><sec id="s7"><title>5. 药效学</title><sec id="s7_1"><title>5.1. 动物模型</title><p>德拉沙星的药效学性质通过小鼠肺感染模型进行了考察。以小鼠肺部感染模型作为实验对象，选取肺炎克雷伯菌，肺炎链球菌和金黄色葡萄球菌各4株检测德拉沙星的药效学指标。将游离德拉沙星的AUC与MIC的比值AUC/MIC确定为预测德拉沙星药效的最可靠参数。结果表明，德拉沙星对肺炎链球菌、金黄色葡萄球菌和肺炎克雷伯菌都显示较好的抗菌活性 [<xref ref-type="bibr" rid="hanspub.28245-ref28">28</xref>]。</p></sec><sec id="s7_2"><title>5.2. 临床试验</title><p>两项II期和两项III期临床试验评估了德拉沙星治疗皮肤和皮肤结构感染(SSSIs)的功效和安全性。在对150名ABSSSI患者进行的第一项II期临床试验中，给予德拉沙星(300 mg和450 mg IV/12 h)与替加环素(首次100 mg IV，随后50 mg/12 h) 5~14天，评估与替加环素相比德拉沙星的安全性和有效性。在每12小时使用300 mg的德拉沙星，每12小时使用450 mg的德拉沙星，以及每12小时使用50 mg替加环素的患者中，治愈率分别为94.3%，92.5%和91.2% [<xref ref-type="bibr" rid="hanspub.28245-ref29">29</xref>]。第二项II期临床试验是在256例ABSSSI患者中进行的，其中蜂窝组织炎患者占45%，脓肿患者28.5%，伤口感染患者25%和烧伤患者1.5%。将德拉沙星(300 mg IV)与万古霉素(每12小时15 mg/kg IV)和利奈唑胺(600 mg IV/12 h)进行比较，考察德拉沙星的疗效。德拉沙星治愈率为70.4%，与利奈唑胺相当(64.9%)，明显高于万古霉素(54.1%)。在MRSA感染的患者中，临床治愈率相似，而在体重指数 ≥ 30 kg/m<sup>2</sup>的患者中，德拉沙星的治愈率更高 [<xref ref-type="bibr" rid="hanspub.28245-ref30">30</xref>]。第一项III期临床研究在660例ABSSS患者中进行，随机选取331名患者每12小时注射德拉沙星300 mg，其余329人每12小时注射万古霉素(15 mg/kg)和氨曲南，5~14天后将德拉沙星单药疗法的功效与万古霉素和氨曲南联合用药进行比较。结果表明，与万古霉素和氨曲南联合用药相比，德拉沙星在48~72小时内在减少原发感染部位的病灶大小方面表现出非劣效性 [<xref ref-type="bibr" rid="hanspub.28245-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.28245-ref32">32</xref>]。在第2项III期临床研究中评估了德拉沙星在革兰氏阳性细菌(包括MRSA)和革兰氏阴性菌引起的ABSSSI中的治疗效果。在由革兰氏阴性病原体引起的ABSSSI患者中，德拉沙星的治疗效果通过肺炎克雷伯菌进行了评估，其MIC<sub>50</sub>，MIC<sub>90</sub>和MIC范围分别为0.12 μg/mL，0.25 μg/mL和0.03~4 μg/mL。在48~72小时，第14天和第21~28天，使用德拉沙星治疗的患者的临床缓解率分别为85.6%、98.7%、97.3%，万古霉素/氨曲南联合用药的缓解率为88.3%、97.6%、97.4% [<xref ref-type="bibr" rid="hanspub.28245-ref33">33</xref>]。在革兰氏阳性菌感染患者中，在48~72小时、第14天和第21~28天德拉沙星与万古霉素/氨曲南的临床缓解率分别为87.9%和87%，97.9%和98.1%，97.2%和97.5%。德拉沙星与万古霉素/氨曲南治疗的MRSA感染微生物根除率分别为98.1%和98.0% [<xref ref-type="bibr" rid="hanspub.28245-ref34">34</xref>]。</p></sec></sec><sec id="s8"><title>6. 安全性和耐受性</title><p>临床研究表明，德拉沙星不良反应的发生与给药剂量有关。在剂量递增研究中，当德拉沙星静脉给药剂量超过800 mg时，50%以上的受试者出现不良反应，然而在整个剂量范围内，德拉沙星口服给药的耐受性良好 [<xref ref-type="bibr" rid="hanspub.28245-ref35">35</xref>]。与其他氟喹诺酮相似，德拉沙星最典型的不良反应是胃肠道相关疾病，包括恶心，腹泻和呕吐。无QT间期延长和光毒性，也没有显示对肝功能、肾功能和葡萄糖利用的不良影响 [<xref ref-type="bibr" rid="hanspub.28245-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.28245-ref37">37</xref>]。</p><p>包括德拉沙星在内的所有氟喹诺酮类抗菌药，都有可能通过靶细菌的拓扑异构酶IV和DNA促旋酶突变产生耐药菌株 [<xref ref-type="bibr" rid="hanspub.28245-ref38">38</xref>]。在体外MRSA中研究了德拉沙星选择耐药性的能力。Remy等人证实德拉沙星在MRSA中选择耐药突变体的概率很低：MRSA菌株的自发德拉沙星耐药频率非常低，预防突变浓度是任何分离株MIC的1~4倍，低于其他喹诺酮类 [<xref ref-type="bibr" rid="hanspub.28245-ref39">39</xref>]。</p></sec><sec id="s9"><title>7. 总结</title><p>从20世纪90年代中期开始，几乎所有的革兰氏阴性和革兰氏阳性病原体对氟喹诺酮类抗菌药的耐药性都开始增加 [<xref ref-type="bibr" rid="hanspub.28245-ref40">40</xref>]。因此，开发具有高效的抗菌活性，抗病原体作用，较高的安全性，并显示增强的药代动力学性质的新型抗菌药是医学研究的重要任务。德拉沙星是一种新型的氟喹诺酮类化合物，其特征在于对革兰氏阳性菌(如MRSA)和革兰氏阴性病原体(包括对喹诺酮耐药的大肠杆菌和肺炎克雷伯菌)具有广谱抗菌活性。德拉沙星凭借其对革兰氏阳性细菌(特别是MRSA)和厌氧菌的低MIC值以及对革兰氏阴性细菌的活性，在治疗细菌感染方面具有很好的应用前景。德拉沙星存在静脉注射和口服给药两种给药途径，应用范围广泛，具有较好的临床应用价值。</p></sec><sec id="s10"><title>8. 展望</title><p>随着抗菌药物的耐药问题日益严重，新型抗菌药物的问世，可以在一定程度上应对该问题。德拉沙星作为新型广谱氟喹诺酮类抗菌药物，为应对急性细菌性皮肤和皮肤结构感染提供了新的选择。另外，由于德拉沙星对大量的高耐药菌显示出了广泛的抗菌活性，它还有可能作为多种严重感染的替代治疗药物，包括复杂性皮肤感染，呼吸系统感染，心内膜炎，复杂尿路感染及其他重症感染性疾病，有望成为临床对抗耐药细菌感染的有力工具，有着潜在的市场价值。</p></sec><sec id="s11"><title>文章引用</title><p>郭忠秋,刘冰弥,刘 宇. 德拉沙星：一种新型氟喹诺酮类广谱抗菌药 Delafloxacin: A Novel Fluoroquinolones Broad-Spectrum Antibacterial[J]. 药物资讯, 2019, 08(01): 9-15. https://doi.org/10.12677/PI.2019.81002</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28245-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">韩伟佳. 目前抗菌药临床应用中的某些问题与对策[J]. 中西医结合心血管病杂志, 2018, 6(8): 26-27.</mixed-citation></ref><ref id="hanspub.28245-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Abbas, M., Paul, M. and Huttner, A. (2017) New and Improved? A Review of Novel Antibiotics for Gram-Positive Bacteria. Clinical Microbiology and Infection, 23, 697-703. &lt;br&gt;https://doi.org/10.1016/j.cmi.2017.06.010</mixed-citation></ref><ref id="hanspub.28245-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Cerceo, E., Deitelzweig, S.B., Sherman, B.M., et al. (2016) Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance, 22, 412-431. &lt;br&gt;https://doi.org/10.1089/mdr.2015.0220</mixed-citation></ref><ref id="hanspub.28245-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Corcione, S., De, R. and Francesco, G. (2018) The Optimal Duration of Treatment for Skin and Soft Tissue Infections and Acute Bacterial Skin and Skin Structure Infections. Current Opinion in Infectious Diseases, 31, 155-162.  
&lt;br&gt;https://doi.org/10.1097/QCO.0000000000000440</mixed-citation></ref><ref id="hanspub.28245-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Jindamwar, P., Roy, P., Chaudhary, C.N., et al. (2016) Novel Reporting of Community Acquired Methicillin Resistant Staphylococcus aureus (CA-MRSA) Strain at a Tertiary Care Centre. International Journal of Current Microbiology and Applied Sciences, 5, 555-564. &lt;br&gt;https://doi.org/10.20546/ijcmas.2016.510.062</mixed-citation></ref><ref id="hanspub.28245-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">高红彦. 喹诺酮类抗菌药应用情况调查及合理用药分析[J]. 山东医学高等专科学校学报, 2017, 39(3): 221-223.</mixed-citation></ref><ref id="hanspub.28245-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">张磊, 毛东东, 陈秋. 2014-2016年平顶山市部分医院喹诺酮类抗菌药的应用分析[J]. 青岛医药卫生, 2018, 50(2): 109-112.</mixed-citation></ref><ref id="hanspub.28245-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Pfaller, M.A., Sader, H.S., Rhomberg, P.R., et al. (2017) In Vitro Activity of Delafloxacin Againstcontemporary Bacterial Pathogens from the United States and Europe, 2014. Antimicrobial Agents and Chemotherapy, 61, e02609-16.  
&lt;br&gt;https://doi.org/10.1128/AAC.02609-16</mixed-citation></ref><ref id="hanspub.28245-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Aldred, K.J., Kerns, R.J. and Osheroff, N. (2014) Mechanism of Quinolone Action and Resistance. Biochemistry, 53, 1565-1574. &lt;br&gt;https://doi.org/10.1021/bi5000564</mixed-citation></ref><ref id="hanspub.28245-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bambeke, V.F. (2014) Renaissance of Antibiotics Against Difficult Infections: Focus on Oritavancin and New Ketolides and Quinolones. Annals of Medicine, 46, 512-529. &lt;br&gt;https://doi.org/10.3109/07853890.2014.935470</mixed-citation></ref><ref id="hanspub.28245-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">毕煌垒, 张佳岳, 刘晓慧, 等. 新型广谱氟喹诺酮类抗菌药物——德拉沙星[J]. 临床药物治疗杂志, 2017, 15(7): 6-10.</mixed-citation></ref><ref id="hanspub.28245-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bambeke, V.F. (2015) Delaﬂoxacin, A Non-Zwitterionic Fluoroquinolone in Phase III of Clinical Development: Evaluation of Its Pharmacology, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy. Future Microbiology, 10, 1111-1123. &lt;br&gt;https://doi.org/10.2217/fmb.15.39</mixed-citation></ref><ref id="hanspub.28245-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bassetti, M., Della, S.P., Pecori, D., et al. (2015) Delafloxacin for the Treatment of Respiratory and Skin Infections. Expert Opinion on Investigational Drugs, 24, 433-442. &lt;br&gt;https://doi.org/10.1517/13543784.2015.1005205</mixed-citation></ref><ref id="hanspub.28245-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bassetti, M., Vena, A., Carnelutti, A., et al. (2018) Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections: Focus on Intravenous Delaﬂoxacin. Infection and Drug Resistance, 11, 479-488.  
&lt;br&gt;https://doi.org/10.2147/IDR.S142140</mixed-citation></ref><ref id="hanspub.28245-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">张建忠. 2017年6月FDA批准新药概况[J]. 上海医药, 2017, 38(15): 95.</mixed-citation></ref><ref id="hanspub.28245-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">王秀娟, 郭彦玲. 一种德拉沙星的制备方法[J]. 精细化工中间体, 2017, 47(1): 56-59.</mixed-citation></ref><ref id="hanspub.28245-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kocsis, B., Domokos, J. and Szabo, D. (2016) Chemical Structure and Pharmacokinetics of Novel Quinolone Agents Represented by Avaroﬂoxacin, Delaﬂoxacin, Fnaﬂoxacin, Zaboﬂoxacin and Nemonoxacin. Annals of Clinical Microbiology and Antimicrobials, 15, 34. &lt;br&gt;https://doi.org/10.1186/s12941-016-0150-4</mixed-citation></ref><ref id="hanspub.28245-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">王亚娟. 氟喹诺酮药物结构改造与抗菌活性研究新进展[J]. 河北化工, 2011, 34(6): 12-18.</mixed-citation></ref><ref id="hanspub.28245-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cho, J.C., Crotty, M.P., White, B.P. and Worley, M.V. (2018) What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone. Pharmacotherapy, 38, 108-121. &lt;br&gt;https://doi.org/10.1002/phar.2050</mixed-citation></ref><ref id="hanspub.28245-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">So, W., Crandon, J.L. and Nicolau, D.P. (2015) Effects or Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella penuemoniae. Journal of Urology, 194, 563-570.</mixed-citation></ref><ref id="hanspub.28245-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Markham, A. (2017) Delafloxacin: First Global Approval. Drugs, 77, 1481-1486.  
&lt;br&gt;https://doi.org/10.1007/s40265-017-0790-5</mixed-citation></ref><ref id="hanspub.28245-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">McCurdy, S., Lawrence, L., Quintas, M., et al. (2017) In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Non-Susceptible S. aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Antimicrobial Agents and Chemotherapy, 61, e00772-17.</mixed-citation></ref><ref id="hanspub.28245-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hoover, R., Hunt, T., Benedict, M., et al. (2016) Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delaﬂoxacin after Single and Multiple Doses in Healthy Volunteers. Clinical Therapeutics, 38, 53-65.  
&lt;br&gt;https://doi.org/10.1016/j.clinthera.2015.11.019</mixed-citation></ref><ref id="hanspub.28245-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">McEwen, A., Lawrence, L., Hoover, R., et al. (2015) Disposition, Metabo-lism and Mass Balance of Delaﬂoxacin in Healthy Human Volunteers Following Intravenous Administration. Xenobiotica, 45, 1054-1062.  
&lt;br&gt;https://doi.org/10.3109/00498254.2015.1042946</mixed-citation></ref><ref id="hanspub.28245-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Hoover, R., Hunt, T., Benedict, M., et al. (2016) Single and Multiple As-cending-Dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. Clinical Therapeutics, 38, 39-52. &lt;br&gt;https://doi.org/10.1016/j.clinthera.2015.10.016</mixed-citation></ref><ref id="hanspub.28245-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Hoover, R., Harry, A.J., Laura, L., et al. (2017) Delaﬂoxacin Pharmacokinet-ics in Subjects with Varying Degrees of Renal Function. The Journal of Clinical Pharmacology, 58, 514-521.</mixed-citation></ref><ref id="hanspub.28245-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Hoover, R., Mar-bury, T.C., Preston, R.A., et al. (2017) Clinical Pharmacology of Delaﬂoxacin in Patients with Hepatic Impairment. The Journal of Clinical Pharmacology, 57, 328-335. &lt;br&gt;https://doi.org/10.1002/jcph.817</mixed-citation></ref><ref id="hanspub.28245-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Lepak, A.J. and Andes, D.R. (2016) In Vivo Phar-macodynamic Target Assessment of Delaﬂoxacin against Staphylococcus aureus, Streptococcus pneumoniae and Klebsiella pneumoni-ae in the Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 60, 4764-4769. &lt;br&gt;https://doi.org/10.1128/AAC.00647-16</mixed-citation></ref><ref id="hanspub.28245-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">O’Riordan, W., Mehra, P., Manos, P., Kingsley, J., Lawrence, L. and Cammarata, S. (2015) A Randomized Phase 2 Study Comparing Two Doses of Delaﬂoxacin with Tigecycline in Adults with Complicated Skin and Skin-Structure Infections. International Journal of Infectious Diseases, 30, 67-73. &lt;br&gt;https://doi.org/10.1016/j.ijid.2014.10.009</mixed-citation></ref><ref id="hanspub.28245-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kingsley, J., Mehra, P., Lawrence, L.E., et al. (2016) A Randomized, Dou-ble-Blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infec-tions Treated with Delaﬂoxacin, Linezolid or Vancomycin. Journal of Antimicrobial Chemotherapy, 71, 821-829.  
&lt;br&gt;https://doi.org/10.1093/jac/dkv411</mixed-citation></ref><ref id="hanspub.28245-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Melinta Therapeutics. A Phase 3, Multicenter, Randomized, Double-Blind, Ac-tive-Controlled Study to Evaluate the Efficacy and Safety of Delaﬂoxacin Compared with Vancomycin plus Aztreonam in Patients with Acute Bacterial Skin and Skin Structure Infections. 2017-3-15/2018-5-25. &lt;br&gt;https://clinicaltrials.gov/ct2/show/NCT01811732</mixed-citation></ref><ref id="hanspub.28245-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Melinta Therapeutics. A Phase 3, Multicenter, Randomized, Double-Blind, Active Controlled Study to Evaluate the Efficacy and Safety of IV and Oral Delaﬂoxacin Compared with Vancomycin plus Aztreonam in Patients with Acute Bacterial Skin and Skin Structure Infections.2017-3-15/2018-5-25. &lt;br&gt;https://clinicaltrials.gov/ct2/show/NCT01984684</mixed-citation></ref><ref id="hanspub.28245-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">O’Riordan, W., Overcash, S., Lawrence, L., et al. (2017) Outcomes with IV/Oral Delaﬂoxacin Compared to Vancomycin/Aztreonam in Treatment of Patients with Acute Bacterial Skin and Skin Structure In-fections (ABSSSI) and Gram-Negative Pathogens. Presented at: IDWeek; San Diego, CA, USA. Poster 1856.</mixed-citation></ref><ref id="hanspub.28245-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Overcash, S., O’Riordan, W., Lawrence, L., et al. (2017) Outcomes with IV/Oral Delaﬂoxacin Compared to Vancomycin/Aztreonam in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Gram-Positive Pathogens. Presented at: IDWeek; San Diego, CA, USA. Poster 1857.</mixed-citation></ref><ref id="hanspub.28245-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Bassetti, M., Pecori, D., Cojutti, P., Righi, E. and Pea, F. (2017) Clinical and Pharmacokinetic Drug Evaluation of Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections. Expert Opinion on Drug Me-tabolism &amp; Toxicology, 13, 1193-1200. &lt;br&gt;https://doi.org/10.1080/17425255.2017.1386654</mixed-citation></ref><ref id="hanspub.28245-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Litwin, J.S., Benedict, M.S., Thorn, M.D., et al. (2015) A Thorough QT Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Car-diac Repolarization. Antimicrobial Agents and Chemotherapy, 59, 3469-3473. &lt;br&gt;https://doi.org/10.1128/AAC.04813-14</mixed-citation></ref><ref id="hanspub.28245-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Ferguson, J., Lawrence, L., Paulson, S., Schlosser, M.J. and Cammarata, S. (2015) Assessment of Phototoxicity Potential of Delaﬂoxacin in Healthy Male and Female Subjects: A Phase 1 Study. Poster Board Number F-1198A. 2015-09-17/2018-05-25. http://melinta.com/wp-content/uploads/2016/03/ICAAC15-Dela_phototoxicity_ph1.pdf</mixed-citation></ref><ref id="hanspub.28245-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Red-grave, L.S., Sutton, S.B., Webber, M.A. and Piddock, L.J.V. (2014) Fluoroquinolone Resistance: Mechanisms, Impact on Bacteria, and Role in Evolutionary Success. Trends in Microbiology, 22, 438-445.  
&lt;br&gt;https://doi.org/10.1016/j.tim.2014.04.007</mixed-citation></ref><ref id="hanspub.28245-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Remy, J.M., Tow-Keogh, C.A., McConnell, T.S., Dalton, J.M. and DeVito, J.A. (2012) Activity of Delafloxacin against Methicillin-Resistant Staphylococcus aureus: Resistance Selection and Characterization. Journal of Antimicrobial Chemotherapy, 67, 2814-2820. &lt;br&gt;https://doi.org/10.1093/jac/dks307</mixed-citation></ref><ref id="hanspub.28245-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">巴合努拉∙赛提哈布勒. 研究氟喹诺酮类药物的不良反应及临床合理用药[J]. 世界最新医学信息文摘, 2018, 18(3): 90-91.</mixed-citation></ref></ref-list></back></article>